Home | Find A Doctor | Contact Us

 

TTP: Phase II study of danazol with plasma exchange and steroids for the treatment of thrombotic thrombocytopenic purpura


Principal Investigator: Mala Varma, MD
Time frame of study: Ongoing
Location of Study:

Mount Sinai Beth Israel
St.Luke's-Mount Sinai Roosevelt

Contact:

Continuum Cancer Research Program
(212) 844-6286

 

Summary:
The standard of care for Thrombotic Thrombocytopenic Purpura (TTP or Moschcowitz syndrome) is plasma exchange (removal and replacement of components of the blood).  TTP is a rare disorder of the blood where blood clots form in blood vessels throughout the body.  The purpose of this clinical study is to find out if the administration of Danazol (a hormonal drug) with plasma exchange and corticosteroids (Prednisone) will reduce the number of plasma exchanges needed to control TTP and if this treatment is better than administering only plasma exchange with corticosteroids.


Eligibility and Treatment Plan:

  • Subject must be between 18 and 60 years of age.
  • New onset or previously diagnosed TTP.
  • PT and PTT normal (Tests used to determine anti-blood clotting function).
  • Subject is not pregnant or breastfeeding.
  • Subject is not positive for HIV, Hepatits B, and Hepatitis C.

Please call for more information

 

 

Privacy Policy | Site Map
Copyright ©  Icahn School of Medicine at Mount Sinai | Mount Sinai Health System